title: Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha.
abstract: The chromosomal translocation products AML1-ETO and PML-RARalpha contribute to the pathogenesis of leukemias. Here, we demonstrate that both AML1-ETO and PML-RARalpha are degraded by the ubiquitin-proteasome system and that their turnover critically depends on the E2-conjugase UbcH8 and the E3-ligase SIAH-1. Contrary to its role in HDAC2 degradation, the E3-ligase RLIM does not target AML1-ETO and PML-RARalpha for ubiquitin-dependent elimination. RLIM rather is a substrate of SIAH-1, which indicates that these E3-ligases operate in a hierarchical order. Remarkably, proteasomal degradation of leukemia fusion proteins, in addition to the block of histone deacetylase (HDAC) enzymatic activity is a consequence of HDAC-inhibitor treatment. The former requires the induction of UbcH8 expression and each of these processes might be beneficial for leukemia treatment. Our observations shed light on the mechanism determining the interplay between E2-conjugases, E3-ligases, and their substrates and suggest a strategy for utilizing the ubiquitylation machinery in a therapeutic setting.
authors: Institute of Biochemistry and Biophysics, University of Jena, Philosophenweg 12, D-07743 Jena, Germany. o.kraemer@uni-jena.de
authors: Oliver H
authors: OH
authors: Krämer
authors: Sylvia
authors: S
authors: Müller
authors: Marc
authors: M
authors: Buchwald
authors: Sigrid
authors: S
authors: Reichardt
authors: Thorsten
authors: T
authors: Heinzel
mesh_terms: D045744:Cell Line, Tumor; D050676:Core Binding Factor Alpha 2 Subunit / Q000378:metabolism*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D009687:Nuclear Proteins / Q000235:genetics / Q000502:physiology; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D000075142:RUNX1 Translocation Partner 1 Protein; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D044763:Ubiquitin-Conjugating Enzymes / Q000502:physiology; D044767:Ubiquitin-Protein Ligases / Q000235:genetics / Q000502:physiology; D054875:Ubiquitination; D014635:Valproic Acid / Q000494:pharmacology; D000098563:Seven in Absentia Proteins
chemical_list: C107844:AML1-ETO fusion protein, human; D050676:Core Binding Factor Alpha 2 Subunit; D056572:Histone Deacetylase Inhibitors; D009687:Nuclear Proteins; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein; D018168:Receptors, Retinoic Acid; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014635:Valproic Acid; C471622:UBE2L6 protein, human; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D000098563:Seven in Absentia Proteins